[Meta] proposal — a flair for co-agonism posts
proposal — a flair for co-agonism posts — with the counter-argument included, because I find it fairly persuasive.
Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 99.6% against a claimed 99.0%, and I posted it because the log needs entries.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
long-acting amylin is the whole point of the molecule
long-acting amylin is the whole point of the molecule
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Which trial and which readout?
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
independent purity data on this compound is thin
This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
read the combination arms separately from the monotherapy arms
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
nothing here is approved as a standalone product and research material is not for human use
amylin and GLP-1 are not redundant pathways
amylin analogue, different receptor family, different story
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
phase 3 data will change most of what gets said here
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
the co-agonism argument is about complementary mechanisms
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
- 1The engineering problem was duration: native amylin is short-acting and…8 comments in this branch · started by u/blunt_coldbox
- 2long-acting amylin is the whole point of the molecule6 comments in this branch · started by u/niels_norgaard